New Summit data could slow US approval plans for PD-1/VEGF drug

biopharmadive.com/news/summit-ivonescimab-pd1-vegf-egfr-lung-cancer-study-results/749401

Dive Brief:
- A dual-acting drug developed by Summit Therapeutics and Akeso delayed tumor progression in a Phase 3 lung cancer trial but didn’t extend survival, complicating its potential path to approval in the U.S.
- When administered alongside chemotherapy, the drug, known as…

This story appeared on biopharmadive.com, 2025-05-31 12:47:15.953000.
The Entire Business World on a Single Page. Free to Use →